2212865
Project Grant
Overview
Grant Description
SBIR Phase I: Detection of Chronic Diseases via Multiplex Analysis of Circulating Metabolites - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel metabolite diagnostic blood test indicative of early-stage diseases including cancer, chronic heart and lung disorders, and diabetes.
The technology analyzes specific panels of blood metabolites indicative of changes in cellular function that occur with disease. This technology reduces the diagnostic interval time from years to weeks or days, diminishes misdiagnosis resulting in improper therapy, and has the potential to alter the use of more invasive diagnostic methods such as biopsies, colonoscopies, and heart catheterizations from an exploratory to a confirmatory role.
This Small Business Innovation Research (SBIR) Phase I project aims to use specific panels of circulating metabolites measured using mass spectrometry (MS) and analyzed using artificial intelligence to detect chronic disease conditions. Pre-clinical models have demonstrated that alterations in metabolism occur at the stage of mild disease, before overt symptoms become evident.
The first specific condition to be evaluated in this project is pulmonary arterial hypertension. The objective is to establish calibrated MS methods with quantified values of multiplexed metabolite panels in a reproducible manner as required for clinical use. Multi-label classifications will also be developed in order to detect and account for various co-morbidities that can affect overall metabolic changes.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The technology analyzes specific panels of blood metabolites indicative of changes in cellular function that occur with disease. This technology reduces the diagnostic interval time from years to weeks or days, diminishes misdiagnosis resulting in improper therapy, and has the potential to alter the use of more invasive diagnostic methods such as biopsies, colonoscopies, and heart catheterizations from an exploratory to a confirmatory role.
This Small Business Innovation Research (SBIR) Phase I project aims to use specific panels of circulating metabolites measured using mass spectrometry (MS) and analyzed using artificial intelligence to detect chronic disease conditions. Pre-clinical models have demonstrated that alterations in metabolism occur at the stage of mild disease, before overt symptoms become evident.
The first specific condition to be evaluated in this project is pulmonary arterial hypertension. The objective is to establish calibrated MS methods with quantified values of multiplexed metabolite panels in a reproducible manner as required for clinical use. Multi-label classifications will also be developed in order to detect and account for various co-morbidities that can affect overall metabolic changes.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Tucson,
Arizona
85747-9108
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Metfora was awarded
Project Grant 2212865
worth $255,706
from National Science Foundation in February 2023 with work to be completed primarily in Tucson Arizona United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Detection of Chronic Diseases via Multiplex Analysis of Circulating Metabolites
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel metabolite diagnostic blood test indicative of early-stage diseases including cancer, chronic heart and lung disorders, and diabetes.The technology analyzes specific panels of blood metabolites indicative of changes in cellular function that occur with disease.This technology reduces the diagnostic interval time from years to weeks or days, diminishes misdiagnosis resulting in improper therapy, and has the potential to alter the use of more invasive diagnostic methods such as biopsies, colonoscopies, and heart catheterizations from an exploratory to a confirmatory role._x000D__x000D__x000D_ This Small Business Innovation Research (SBIR) Phase I project aims to use specific panels of circulating metabolites measured using mass spectrometry (MS) and analyzed using artificial intelligence to detect chronic disease conditions. Pre-clinical models have demonstrated that alterations in metabolism occur at the stage of mild disease, before overt symptoms become evident. The first specific condition to be evaluated in this project is pulmonary arterial hypertension. The objective is to establish calibrated MS methods with quantified values of multiplexed metabolite panels in a reproducible manner as required for clinical use. Multi-label classifications will also be developed in order to detect and account for various co-morbidities that can affect overall metabolic changes._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 21-562
Status
(Complete)
Last Modified 2/6/23
Period of Performance
2/1/23
Start Date
1/31/24
End Date
Funding Split
$255.7K
Federal Obligation
$0.0
Non-Federal Obligation
$255.7K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2212865
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
ZTR1XDS9C1H4
Awardee CAGE
8NF89
Performance District
Not Applicable
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $255,706 | 100% |
Modified: 2/6/23